Tenofovir-based pre-exposure prophylaxis for HIV prevention
about
sameAs
Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effectsCombination prevention: new hope for stopping the epidemicPreconception and contraceptive care for women living with HIVOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesStampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSPrevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesPersonalized Biobehavioral HIV Prevention for Women and Adolescent Girls.A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.The Surprising Role of Amyloid Fibrils in HIV InfectionBarriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research.Effects of messaging about multiple biomedical and behavioral HIV prevention methods on intentions to use among US MSM: results of an experimental messaging study.The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South AfricaHIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.Reproductive assistance in HIV serodiscordant couples.HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women.An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural GhanaProphylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance.Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".Curriculum development to increase minority research literacy for HIV prevention research: a CBPR approachMacaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.Qualitative evaluation of a Positive Prevention training for health care providers in Mozambique.Amyloid formation: functional friend or fearful foe?Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies.Maximizing the impact of HIV prevention efforts: interventions for couples.The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition.An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV TransmissionHow effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.Griffithsin protects mice from genital herpes by preventing cell-to-cell spreadHIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples.Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.
P2860
Q24610019-64A9CC96-5E46-450A-A610-B7C9CC9B1B77Q24630559-D126E261-A616-4470-9078-5B91A4974FC1Q27012918-806D5515-BC9B-46A5-A211-752DBA0FF448Q27023352-0CA14520-0596-44CA-9DC3-8EFD6496B14EQ28260539-C9CEBA92-780E-4514-A61D-BE4B09155E12Q28486101-16BB7B4B-BEE2-41A8-8220-3B13CF06A2D4Q28540200-956AC0B2-65A0-478D-A5A3-34DF0BB3CA9BQ30357818-E63C3A26-3F1C-46D3-A71E-C373EB61926CQ30431343-07445F52-A661-4723-8EB5-75FE93998C57Q33570363-59822F3E-751D-41E6-A571-4AD6E13FB59AQ33733039-70D1D0CB-1293-4CEC-A27F-A84B5A359069Q33821090-71F36357-8120-4646-8DE7-CE4746F0805AQ34022053-088AA45D-C8E5-43E8-9E0F-E193DFC887BEQ34022092-9904C5AC-3FBD-4852-99A2-EF8D9D8902C1Q34205161-FE63A263-63AD-4084-8193-27873718B655Q34249966-2B4BC45E-5943-4AE2-88F9-5C2B4007DCEBQ34311329-9BC20607-DC4A-434B-ACD3-74B7AFB1AFB8Q34339523-98B1A759-D32D-4DE7-AF50-9AF85595DED1Q34405887-048431FB-3E0E-4030-BEDA-3BCE72D56E5AQ34462922-01578922-DDDF-47BB-BEAE-A0ACF5DA1342Q34495644-E322CDE7-FE9A-49E9-BA5C-1989FD882E18Q34506545-1688631E-8759-4128-9C30-F1A4C3A303D3Q34559293-2668EEBE-43A2-47E3-A690-7F938B48AD8CQ34921423-7F741F2D-AFB3-4A5D-89E9-7B8DD2AC61F7Q35561488-3C3D8637-95D7-4935-91B5-28C4A6D38D49Q35629391-732EE58A-DCA2-4B67-9A75-32B47CEC4AB9Q36001347-02F4B5B2-55C0-4C7D-B628-41B94AE3F6A4Q36002873-4AAE4024-8C0F-4A71-A253-C3CA5A57C064Q36010357-7F44F12A-E92C-493A-8733-09F704322B87Q36051764-40A2F8F2-E841-42EB-B2D3-C95D6E413E0FQ36188123-E50AFBF7-B8F8-4A2C-BF5E-F60BE57C9025Q36331519-C3AA8342-BBEC-4FE9-8CAA-7AD5F2719CB2Q36359133-C5FFDEC1-A5C7-4B61-BBFF-F0B97405E439Q36386787-46D891CE-DB69-44AA-A28E-52064ED67942Q36681727-C3BC3DD0-434F-4AB4-B34D-BA9FFAA365E9Q36770118-4145AE81-655C-416D-909F-06AD441E29F6Q36778722-D64E8978-17D7-4DBB-8DFC-CABE4F870768Q36827173-F39FB39C-F82D-45A6-877D-2B371DADA7F5Q36866833-98E7B941-B471-4471-A8E4-62D89631225EQ36891072-3C32CD18-0997-4ECC-9909-7DABC97C63F5
P2860
Tenofovir-based pre-exposure prophylaxis for HIV prevention
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@ast
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@en
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@nl
type
label
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@ast
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@en
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@nl
altLabel
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence
@en
prefLabel
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@ast
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@en
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@nl
P2860
P921
P3181
P1476
Tenofovir-based pre-exposure prophylaxis for HIV prevention
@en
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence
@en
P2093
Jared M Baeten
Jared M. Baeten
P2860
P3181
P356
10.1097/QCO.0B013E32834EF5EF
P407
P50
P577
2012-02-01T00:00:00Z